litlas
Log inCreate account

Marc C. Chamberlain

Active 1988–2025

111
Papers
21,726
Citations
85
h-index
110
i10-index

Citations

Citations per year for Marc C. Chamberlain1984: 1 citations1986: 1 citations1989: 1 citations1990: 3 citations1992: 1 citations1993: 14 citations1994: 2 citations1995: 10 citations1996: 13 citations1997: 17 citations1998: 42 citations1999: 20 citations2000: 30 citations2001: 17 citations2002: 32 citations2003: 27 citations2004: 39 citations2005: 77 citations2006: 69 citations2007: 36 citations2008: 67 citations2009: 98 citations2010: 168 citations2011: 211 citations2012: 171 citations2013: 204 citations2014: 202 citations2015: 185 citations2016: 192 citations2017: 226 citations2018: 200 citations2019: 689 citations2020: 757 citations2021: 590 citations2022: 528 citations2023: 386 citations2024: 545 citations2025: 236 citations2026: 6 citations1985: no citations, so this year is not shown1987–1988: no citations, so these years are not shown1991: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,084 citing papers, 28.3% of this breakdownGermany: 629 citing papers, 8.5% of this breakdownChina: 483 citing papers, 6.5% of this breakdownItaly: 448 citing papers, 6.1% of this breakdownUnited Kingdom: 388 citing papers, 5.3% of this breakdownFrance: 364 citing papers, 4.9% of this breakdownNetherlands: 317 citing papers, 4.3% of this breakdownSwitzerland: 288 citing papers, 3.9% of this breakdownCanada: 257 citing papers, 3.5% of this breakdownSpain: 179 citing papers, 2.4% of this breakdownAustria: 154 citing papers, 2.1% of this breakdownJapan: 153 citing papers, 2.1% of this breakdown
0%28.3%Other 22.1%

Institutions

Fields

  • Medicine80.8%
  • Biochemistry, Genetics and Molecular Biology9.3%
  • Materials Science3%
  • Neuroscience2.4%
  • Engineering1.1%
  • Immunology and Microbiology1.1%
  • Other2.3%

Topics

  • Glioma Diagnosis and Treatment20%
  • Brain Metastases and Treatment10.3%
  • Meningioma and schwannoma management4.8%
  • Radiomics and Machine Learning in Medical Imaging3.3%
  • Lung Cancer Research Studies2.6%
  • MRI in cancer diagnosis2.3%
  • Other56.7%

Coauthors

All papers

Open in search
  1. Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

    Authors: Patrick Y. Wen, David R. Macdonald, David A. Reardon, Timothy F. Cloughesy, A. Gregory Sorensen, Evanthia Galanis, John DeGroot, Wolfgang Wick, Mark R. Gilbert, Andrew B. Lassman, Christina Tsien, Tom Mikkelsen, Eric T. Wong, Marc C. Chamberlain, Roger Stupp, Kathleen R. Lamborn, Michael A. Vogelbaum, Martin J. van den Bent, Susan M. Chang - Journal of Clinical Oncology 2010 cited by 3,829

  2. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas

    Authors: Martin J. van den Bent, JS Wefel, David Schiff, M. J. B. Taphoorn, Kurt A. Jaeckle, Larry Junck, Terri S. Armstrong, Ali Choucair, Adam Waldman, Thierry Gorlia, Marc C. Chamberlain, BG Baumert, MA Vogelbaum, DR Macdonald, DA Reardon, PY Wen, SM Chang, AH Jacobs - The Lancet Oncology 2011 cited by 645

  3. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas

    Authors: Nathalie L. Albert, Michael Weller, Bogdana Suchorska, Norbert Galldiks, Riccardo Soffietti, Michelle M. Kim, Christian la Fougère, Whitney B. Pope, Ian Law, Javier Arbizu, Marc C. Chamberlain, Michael A. Vogelbaum, Ben M. Ellingson, J. C. Tonn - Neuro-Oncology 2016 cited by 745

  4. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review

    Authors: Leland Rogers, Igor J. Barani, Marc C. Chamberlain, Thomas Kaley, Michael McDermott, Jeffrey Raizer, David Schiff, Damien C. Weber, Patrick Y. Wen, Michael A. Vogelbaum - Journal of neurosurgery 2014 cited by 696

  5. Leptomeningeal metastases: a RANO proposal for response criteria

    Authors: Marc C. Chamberlain, Larry Junck, Dieta Brandsma, Riccardo Soffietti, Roberta Rudà, Jeffrey J. Raizer, Willem Boogerd, Sophie Taillibert, Morris D. Groves, Émilie Le Rhun, Julie Walker, Martin J. van den Bent, Patrick Y. Wen, Kurt A. Jaeckle - Neuro-Oncology 2016 cited by 319

  6. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria

    Authors: Lakshmi Nayak, Lisa M. DeAngelis, Alba A. Brandes, David M. Peereboom, Evanthia Galanis, Nancy U. Lin, Riccardo Soffietti, David R. Macdonald, Marc C. Chamberlain, James Perry, Kurt A. Jaeckle, Minesh P. Mehta, Roger Stupp, Alona Muzikansky, Elena Pentsova, Timothy F. Cloughesy, Fábio M. Iwamoto, J. C. Tonn, Michael A. Vogelbaum, Patrick Y. Wen, Martin J. van den Bent, David A. Reardon - Neuro-Oncology 2017 cited by 244

  7. Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer

    Authors: Virginia F. Borges, Cristiano Ferrario, Nathalie Aucoin, Carla I. Falkson, Qamar J. Khan, Ian E. Krop, Stephen Welch, Alison Conlin, Jorge Chaves, Philippe L. Bédard, Marc C. Chamberlain, Todd Gray, Alex Vo, Erika Hamilton - JAMA Oncology 2018 cited by 165

  8. Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

    Authors: Wolfgang Wick, Vinay K. Puduvalli, Marc C. Chamberlain, Martin J. van den Bent, Alain Carpentier, Lawrence Cher, Warren Mason, Michael Weller, Shengyan Hong, Luna Musib, Astra M. Liepa, Donald Thornton, Howard A. Fine - Journal of Clinical Oncology 2010 cited by 514

  9. A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma

    Authors: Kathryn E. Beckermann, Amita Patnaik, Ira Winer, Winston Tan, Babar Bashir, Christos E. Kyriakopoulos, Randy F. Sweis, Marc C. Chamberlain, Brian I. Rini - Investigational New Drugs 2024 cited by 30

  10. PET imaging in patients with brain metastasis—report of the RANO/PET group

    Authors: Norbert Galldiks, Karl‐Josef Langen, Nathalie L. Albert, Marc C. Chamberlain, Riccardo Soffietti, Michelle M. Kim, Ian Law, Émilie Le Rhun, Susan M. Chang, Julian Schwarting, Stephanie E. Combs, Matthias Preusser, Peter Forsyth, Whitney B. Pope, Michael Weller, Jörg C. Tonn - Neuro-Oncology 2019 cited by 194

  11. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study

    Authors: Grant A. McArthur, Michele Maio, Ana Arance, Paul Nathan, Christian U. Blank, Marie‐Françoise Avril, Claus Garbe, Axel Hauschild, Dirk Schadendorf, Omid Hamid, Michael Fluck, Melissa S. Thebeau, Jacob Schachter, Richard Kefford, Marc C. Chamberlain, Martina Makrutzki, Susan Robson, René González, Kim Margolin - Annals of Oncology 2016 cited by 246

  12. Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee

    Authors: Katherine E. Warren, Gilbert Vézina, Tina Young Poussaint, Monika Warmuth‐Metz, Marc C. Chamberlain, Roger J. Packer, Alba A. Brandes, Moshe Reiss, Stewart Goldman, Michael J. Fisher, Ian F. Pollack, Michael D. Prados, Patrick Y. Wen, Susan M. Chang, Christelle Dufour, David Zurakowski, Rolf D. Kortmann, Mark W. Kieran - Neuro-Oncology 2017 cited by 128

  13. Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma

    Authors: Marc C. Chamberlain, Christina S. Baik, Vijayakrishna K. Gadi, Shailender Bhatia, Laura Q.M. Chow - Neuro-Oncology 2016 cited by 223

  14. Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials

    Authors: Edward K. Avila, Marc C. Chamberlain, David Schiff, Jaap C. Reijneveld, Terri S. Armstrong, Roberta Rudà, Patrick Y. Wen, Michael Weller, Johan A F Koekkoek, Sandeep Mittal, Yoshiki Arakawa, Ali Choucair, Jorge González-Martínez, David Macdonald, Ryo Nishikawa, Aashit Shah, Charles J. Vecht, Paula Warren, Martin J. van den Bent, Lisa M. DeAngelis - Neuro-Oncology 2016 cited by 128

  15. Chemotherapy-Related Neurotoxicity

    Authors: Sophie Taillibert, Émilie Le Rhun, Marc C. Chamberlain - Current Neurology and Neuroscience Reports 2016 cited by 122

  16. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.

    Authors: Michael Glantz, Kurt A. Jaeckle, Marc C. Chamberlain, Surasak Phuphanich, Lawrence D. Recht, L. J. Swinnen, B Maria, S LaFollette, Günter Schumann, Bernard F. Cole, Stephen B. Howell - 1999 cited by 528

  17. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy

    Authors: Patrick Y. Wen, Jan Drappatz, John de Groot, Michael D. Prados, David A. Reardon, David Schiff, Marc C. Chamberlain, Tom Mikkelsen, Annick Desjardins, Jaymes Holland, Jerry Ping, Ron Weitzman, Timothy F. Cloughesy - Neuro-Oncology 2017 cited by 116

  18. A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients

    Authors: Brain Tumor Trials Collaborative, Jeffrey J. Raizer, Pierre Giglio, Jethro Hu, Mari L. Groves, Ryan Merrell, C. Conrad, Surasak Phuphanich, Vinay K. Puduvalli, Monica Loghin, Nina A. Paleologos, Ying Yuan, D. Liu, Alfred Rademaker, W.K. Alfred Yung, Brian Vaillant, Jeremy Rudnick, Marc C. Chamberlain, Nicholas A. Vick, Sean Grimm, Ivo W. Tremont‐Lukats, John de Groot, Kenneth Aldape, Mark R. Gilbert - Journal of Neuro-Oncology 2015 cited by 81

  19. A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma

    Authors: Vinay K. Puduvalli, Jing Wu, Ying Yuan, Terri S. Armstrong, Elizabeth Vera, Jimin Wu, Jihong Xu, Pierre Giglio, Howard Colman, Tobias Walbert, Jeffrey J. Raizer, Morris D. Groves, David Tran, Fábio M. Iwamoto, Nicholas G. Avgeropoulos, Nina A. Paleologos, Karen Fink, David M. Peereboom, Marc C. Chamberlain, Ryan Merrell, Marta Penas Prado, W.K. Alfred Yung, Mark R. Gilbert - Neuro-Oncology 2020 cited by 46

  20. Adult Primary Intradural Spinal Cord Tumors: A Review

    Authors: Marc C. Chamberlain, Trent L. Tredway - Current Neurology and Neuroscience Reports 2011 cited by 338

  21. Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas

    Authors: Marc C. Chamberlain - Expert Review of Neurotherapeutics 2010 cited by 188

  22. Central Nervous System Cancers, Version 1.2015

    Authors: Burt Nabors, Jana Portnow, Mario Ammirati, Joachim M. Baehring, Henry Brem, Paul D. Brown, Nicholas Butowski, Marc C. Chamberlain, Robert A. Fenstermaker, Allan H. Friedman, Mark R. Gilbert, Jona A. Hattangadi‐Gluth, Matthias Holdhoff, Larry Junck, Thomas Kaley, Ronald Lawson, Jay S. Loeffler, Mary Lovely, Paul L. Moots, Maciej M. Mrugała, Herbert B. Newton, Ian F. Parney, Jeffrey J. Raizer, Lawrence D. Recht, Nicole Shonka, Dennis C. Shrieve, Allen K. Sills, Lode J. Swinnen, David Tran, Nam Tran, Frank D. Vrionis, Stephanie E. Weiss, Patrick Y. Wen, Nicole R. McMillian, Anita M. Engh - Journal of the National Comprehensive Cancer Network 2015 cited by 178

  23. Gender disparity in the rate of partner abandonment in patients with serious medical illness

    Authors: Michael Glantz, Marc C. Chamberlain, Qin Liu, Chung‐Cheng Hsieh, Keith R. Edwards, Alixis Van Horn, Lawrence D. Recht - Cancer 2009 cited by 144

  24. A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma

    Authors: Priya Kumthekar, Sean Grimm, Roxanne T Aleman, Marc C. Chamberlain, David Schiff, Patrick Y. Wen, Fábio M. Iwamoto, Demirkan Gursel, David A. Reardon, Benjamin Purow, Masha Kocherginski, Irene Helenowski, Jeffrey J. Raizer - Neuro-Oncology Advances 2022 cited by 37